Search clinical trials for: DS1062

Total 9 results

AstraZeneca
Daiichi Sankyo

Active, not recruiting

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Breast Cancer

Belgium, Canada, France, Italy, Spain, United Kingdom, Hungary, Poland, United States, Korea, Republic of, Brazil, India, Japan, Russian Federation, China, Taiwan, Netherlands, Germany, South Africa, Argentina
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Breast Cancer

United States, Spain, China, Italy, Australia, United Kingdom, Korea, Republic of, Vietnam, Japan, Turkey, Brazil, Taiwan, Thailand, Canada, Argentina, India, France, Singapore, Mexico, Germany, Philippines, Poland, South Africa
Daiichi Sankyo
AstraZeneca

Available

Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients

Advanced Non-Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer

United States
Daiichi Sankyo Co., Ltd.
AstraZeneca; Daiichi Sankyo, Inc.

Recruiting

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Hormone Receptor Positive Breast Cancer

United States, Japan
Daiichi Sankyo
AstraZeneca

Active, not recruiting

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

Non-small Cell Lung Cancer

United States, Spain, Korea, Republic of, Taiwan, Germany, Italy, Japan, France, Hungary, Netherlands
Daiichi Sankyo
AstraZeneca

Active, not recruiting

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

Non-small Cell Lung Cancer

United States, Germany, Spain, Japan, Canada, France, Korea, Republic of, Italy, United Kingdom, China, Taiwan, Hungary, Singapore, Switzerland, Netherlands, Brazil, Mexico, Russian Federation, Puerto Rico, Poland, Hong Kong, Romania and more
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

Metastatic Non Small Cell Lung Cancer

Belgium, Australia, United States, Korea, Republic of, Spain, China, France, Germany, Thailand, Brazil, Japan, Hong Kong, Austria, Greece, Switzerland, Netherlands, Romania, Hungary, Italy, Chile, Taiwan, Poland, Canada, Argentina, Turkey
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

Metastatic Non Small Cell Lung Cancer

United States, China, Belgium, Portugal, Japan, Taiwan, France, United Kingdom, Spain, Hungary, Thailand, Germany, Italy, Switzerland, Hong Kong, Korea, Republic of, Australia, Mexico, Brazil, Netherlands, Romania, Argentina, Chile, G... and more
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Active, not recruiting

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Advanced or Metastatic NSCLC

United States, Spain, Taiwan, Japan, Italy

Search clinical trials for: DS1062

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations